Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: Preliminary results

Reproductive BioMedicine Online

Volumn 20, Issue 2, 2010, Pages 280-285

  Decanter, Christine ^a,b   Morschhauser, Franck ^a,b   Pigny, Pascal ^a,b   Lefebvre, Catherine ^a,b   Gallo, Cécile ^a,b   Dewailly, Didier ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

AMH; Chemotherapy; Follicular depletion; Follow up; Lymphoma

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LEUPRORELIN; MELPHALAN; MITOGUAZONE; MUELLERIAN INHIBITING FACTOR; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; FEMALE FERTILITY; FOLLOW UP; HODGKIN DISEASE; HUMAN; MUELLERIAN DUCT; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVARY FOLLICLE CELL; PATIENT COUNSELING; PRESERVATION; PROSPECTIVE STUDY; PROTEIN DETERMINATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77649200868     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.11.010     Document Type: Article

References (37)

1. Anderson, R.A., Themmen, A.P., Al-Qahtani, A., et al., 2006. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum. Reprod. 21, 2583-2592.
2. Ataya, K., Ramahi-Ataya, A., 1993. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod. Toxicol. 7, 229-235.
3. Bath, L.E., Wallace, W.H., Shaw, M.P., et al., 2003. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum. Reprod. 18, 2368-2374.
4. Blumenfeld, Z., Dann, E., Avivi, I., et al., 2002. Fertility after treatment for Hodgkin's disease. Ann. Oncol. 13 (Suppl. 1), 138-147.
5. Byrne, J., Fears, T.R., Gail, M.H., et al., 1992. Early menopause in long-term survivors of cancer during adolescence. Am. J. Obstet. Gynecol. 166, 788-793.
6. Durlinger, A.L., Visser, J.A., Themmen, A.P., 2002. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction 124, 601-609.
7. Familiari, G., Caggiati, A., Nottola, S.A., et al., 1993. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum. Reprod. 12, 2080-2087.
8. Fanchin, R., Schonäuer, L.M., Righini, C., et al., 2003a. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum. Reprod. 18, 323-327.
9. Fanchin, R., Schonäuer, L.M., Righini, C., et al., 2003b. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum. Reprod. 18, 328-332.
10. Fanchin, R., Taieb, J., Lozano, D.H., et al., 2005. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum. Reprod. 20, 923-927.
11. Gougeon, A., Ecochard, R., Thalabard, J.C., 1994. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol. Reprod. 50, 653-663.
12. Harris, N.L., Jaffe, E.S., Diebold, J., et al., 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17, 3835-3849.
13. Hehenkamp, W.J., Looman, C.W., Themmen, A.P., et al., 2006. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab. 91, 4057-4063.
14. Jayaprakasan, K., Campbell, B.K., Hopkisson, J.F., et al., 2008. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum. Reprod. 23, 2577-2583.
15. Larsen, E.C., Müller, J., Schmiegelow, K., et al., 2003. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J. Clin. Endocrinol. Metab. 88, 5307-5314.
16. Lie Fong, S., Lugtenburg, P.J., Schipper, I., et al., 2008. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum. Reprod. 23, 674-678.
17. Lutchman Singh, K., Davies, M., Chatterjee, R., 2005. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum. Reprod. Update 11, 69-89.
18. Lutchman Singh, K., Muttukrishna, S., Stein, R.C., et al., 2007. Predictors of ovarian reserve in young women with breast cancer. Br. J. Cancer 96, 1808-1816.
19. Mackie, E.J., Radford, M., Shalet, S.M., 1996. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med. Pediatr. Oncol. 27, 74-78.
20. Marcello, M.F., Nuciforo, G., Romeo, R., et al., 1990. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 66, 2099-2104.
21. Meirow, D., 2000. Reproduction post-chemotherapy in young cancer patients. Mol. Cell. Endocrinol. 169, 123-131.
22. Meirow, D., Nugent, D., 2001. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update 7, 535-543.
23. Meirow, D., Dor, J., Kaufman, B., et al., 2007. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum. Reprod. 22, 1626-1633.
24. Meirow, D., Lewis, H., Nugent, D., Epstein, M., 1999. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum. Reprod. 14, 1903-1907.
25. Mohamed, K.A., Davies, W.A., Lashen, H., 2006. Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil. Steril. 86, 1515-1517.
26. Oktem, O., Oktay, K., 2007a. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110, 2222-2229.
27. Oktem, O., Oktay, K., 2007b. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 67, 10159-10162.
28. Perez, G.I., Knudson, C.M., Leykin, L., et al., 1997. Apoptosis-associated signalling pathways are required for chemotherapy-mediated female germ cell destruction. Nat. Med. 3, 1228-1232.
29. Pigny, P., Jonard, S., Robert, Y., Dewailly, D., 2006. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 941-945.
30. Rosendahl, M., Andersen, C.Y., la Cour Freiesleben, N., Juul, A., Løssl, K., Andersen, A.N., 2009. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil. Steril.
31. Seifer, D. B., Maclaughlin, D.T., 2007. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil. Steril. 88, 539-546.
32. Somunkiran, A., Yavuz, T., Yucel, O., Ozdemir, I., 2007. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 134, 196-201.
33. Streuli, I., Fraisse, T., Pillet, C., et al., 2008. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil. Steril. 90, 395-400.
34. Tsepelidis, S., Devreker, F., Demeestere, I., et al., 2007. Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22, 1837-1840.
35. van Beek, R.D., van den Heuvel-Eibrink, M.M., Laven, J.S., et al., 2007. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J. Clin. Endocrinol. Metab. 92, 3869-3874.
36. van Disseldorp, J., Faddy, M.J., Themmen, A.P., et al., 2008. Relationship of serum antimüllerian hormone concentration to age at menopause. J. Clin. Endocrinol. Metab. 93, 2129-2134.
37. van Rooij, I.A., Broekmans, F.J., te Velde, E.R., et al., 2002. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17, 3065-3071.